Related Experiment Videos
[Rituximab in cold agglutinin disease]
F Camou1, J-F Viallard, J-L Pellegrin
1Service de médecine interne, centre François-Magendie, hôpital du Haut-Lévêque, CHU de Bordeaux, avenue Magellan, 33604 Pessac cedex, France.
La Revue De Medecine Interne
|July 31, 2003
Summary
Rituximab effectively treats cold agglutinin disease, a rare autoimmune anemia. This study shows rituximab (anti-CD20 antibody) induced remission in all patients, offering a new treatment option.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia linked to lymphoproliferative disorders.
- It involves auto-anti-erythrocyte IgM antibodies, causing hemolytic crises and vascular issues in cold conditions.
- Currently, no definitive treatment exists for CAD.
Observation:
- This study evaluated rituximab (anti-CD20 monoclonal antibody) in 5 CAD patients.
- Patients received 4 weekly infusions of rituximab.
- A literature review included 23 additional CAD cases treated with rituximab.
Findings:
- Rituximab demonstrated good tolerance and induced remission in all 5 patients (4 partial, 1 complete).
- Literature review showed a 21/23 response rate in similar cases, with 14 complete remissions.
- Rituximab treatment led to significant clinical improvement in cold agglutinin disease.
Implications:
- Rituximab represents a promising alternative treatment for cold agglutinin disease.
- This therapy offers hope for patients with this rare and debilitating condition.
- Further research may solidify rituximab's role in managing CAD.